CombiGene
2.6
SEK
+4.84 %
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+4.84%
+0.78%
+5.69%
-6.47%
-20.73%
-3.35%
-4.94%
-79.75%
-89.22%
-97.29%
combigene.com
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Revenue
5.54M
EBIT %
-696.75 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
COMBI
Daily low / high price
2.46 / 2.6
SEK
Market cap
51.48M SEK
Turnover
11.79K SEK
Volume
4.6K
Financial calendar
Extraordinary general meeting
2024-12-10
Annual report
2025-02-14
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Orpahazyme AS | 10.0 % | 10.0 % |
| Jan Ivar Nordqvist | 9.5 % | 9.5 % |
| Avanza Pension | 6.0 % | 6.0 % |
| M&L Industriförvaltning AB | 3.0 % | 3.0 % |
| Nordnet Pensionsförsäkring AB | 2.6 % | 2.6 % |
| Thoren Tillväxt AB | 2.5 % | 2.5 % |
| Molse, Oliver | 2.3 % | 2.3 % |
| Ferstad, Arne | 1.5 % | 1.5 % |
| Olsson, Per Magnus | 1.3 % | 1.3 % |
| Thomassen Skaar, Christian | 1.3 % | 1.3 % |
ShowingAll content types
Shareholders’ proposal for election of Board of Directors
Aktieägares förslag till val av styrelse i CombiGene
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools